Short answer
OMEROS CORP (OMER) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $36M with net income of −$57M.
Q3 2026 key financials · XBRL
- Revenue
- $36M
- +26.0% QoQ
- Net income
- −$57M
- −85.5% YoY · −533.5% QoQ
- Operating margin
- 12.5%
- EPS (diluted)
- −$0.64
- −39.1% YoY · −526.7% QoQ
Source: XBRL data from the OMEROS CORP (OMER) Q3 2026 10-Q on SEC EDGAR. USD.
OMEROS CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $35.9M vs $0 YoY, following YARTEMLEA launch in January 2026
- Gross margin approximately 100% in Q3, reflecting low-cost pre-approval inventory
- YARTEMLEA: $35.9M net sales, 109 ordering accounts, up 49% from June 30
- Cash, equivalents and short-term investments $95.3M; operating cash flow $13.3M
- Q4 R&D and SG&A expected higher; EU authorization not expected after negative CHMP opinion
Risk Factors
- New market risk: $100.0 million share repurchase program may increase stock-price volatility
- Program discretion: repurchases may be suspended or terminated anytime, with $90.1 million remaining November 16, 2026
- Liquidity risk: repurchases could potentially reduce market liquidity for common stock
- Valuation risk: stock price may decline below repurchase prices, reducing shareholder value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMEROS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.